Table 1 FDA-approved agents for the treatment of diffuse large B cell lymphoma
From: New agents and regimens for diffuse large B cell lymphoma
| Agent | Approved date | Study | Dose schedulea | Number of patientsa | Efficacya |
|---|---|---|---|---|---|
| Tafasitamab-cxix (Monjuvi) | July 31, 2020 | NCT02399085 |
12 mg/kg as an intravenous infusion according to the following dosing schedule Cycle 1: Days 1, 4, 8, 15, and 22 of the 28-day cycle Cycles 2 and 3: Days 1, 8, 15, and 22 of each 28-day cycle Cycle 4 and beyond: Days 1 and 15 of each 28-day cycle | 80 | ORR: 55%; CR: 37% |
| Selinexor (XPOVIO) | June 22, 2020 | NCT02227251 | 60 mg orally on days 1 and 3 of each week | 134 | CR: 13%; ORR: 29% |
| Polatuzumab vedotin-piiq (Polivy) | June 10, 2019 | NCT02257567 | 1.8 mg/kg for six 21-day cycle with bendamustine and a rituximab product | 80 | CR: 40%; ORR: 63% |
| Tisagenlecleucel (Kymriah) | May 1, 2018 | NCT02445248 | 0.6–6.0 × 108 CAR-positive viable T cells | 68 | CR: 32%; ORR: 50% |
| Axicabtagene ciloleucel (Yescarta) | October 18, 2017 | NCT02348216 | 2.0 × 106 /kg CAR-positive viable T cells (maximum 2 × 108) | 108 | CR: 51%; ORR: 72% |
| Hyaluronidase human and rituximab (RITUXAN HYCELA) | June 22, 2017 | NCT01649856 | 1400 mg subcutaneous rituximab and 23,400 units hyaluronidase human, with CHOP | 381 | CR: 51%; ORR: 83% |
| Rituximab (Rituxan) | February 10, 2006 | LNH 98–5/GELA | rituximab 375 mg/m2 with CHOP | 399 | CR:75%; 2-y OS: 69% |
| E4494 | rituximab 375 mg/m2 with CHOP | 632 | 2-y OS: 74%; PFS: 3.1 years | ||
| MInT | rituximab 375 mg/mm2 with CHOP/CHOP-like regimens | 823 | 2-y OS: 95% |